Title

Overexpression of phospholipase A2 group IIA in esophageal squamous cell carcinoma and association with cyclooxygenase-2 expression

Document Type

Journal Article

Publisher

Asian Pacific Organization for Cancer Prevention

Faculty

Faculty of Health, Engineering and Science

School

School of Medical Sciences

RAS ID

18168

Comments

This article was originally published as: Zhai Y.-C., Dong B., Wei W.-Q., He Y., Li X.-Q., Cormier R.T., Wang W., Liu F. (2014). Overexpression of phospholipase A2 group IIA in esophageal squamous cell carcinoma and association with cyclooxygenase-2 expression. Asian Pacific Journal of Cancer Prevention, 15(21), 9417-9421. Original article available here

Abstract

Background: Esophageal cancer is one of the most frequently occurring malignancies and the seventh leading cause of cancer-related deaths in the world. The esophageal squamous cell carcinoma (ESCC) is the most common histological type of esophageal cancer worldwide. Materials and Methods: Our goal in this study was to detect phospholipase A2 Group IIA (PLA2G2A) and cyclooxygenase-2 (COX-2) immuno-expression in ESCC in a high-risk population in China. Results: Positive expression of PLA2G2A protein was observed in 57.2% (166/290) of the cases, while COX-2 was found in 257 of 290 samples (88.6%), both PLA2G2A and COX-2 being expressed in 153 cases (52.8%), with a significant agreement (Kappa=0.091, p=0.031).Overexpression of PLA2G2A was significantly correlated with the depth of invasion (p=0.001). Co-expression of PLA2G2A and COX-2 not only significantly correlated with the depth of invasion (p=0.004) but also with TNM stage (p=0.04). Conclusions: Our results showed that in patients with ESCC, PLA2G2A overexpression and PLA2G2A co-expression with COX-2 is significantly correlated with advanced stage. The biological role and pathophysiologic regulation of PLA2G2A and COX-2 overexpression in ESCC deserve further investigation.

DOI

10.7314/APJCP.2014.15.21.9417

Share

 
COinS